Rationale: Pulmonary hypertension is a fatal disease; however, its pathogenesis still remains to be elucidated.
C hronic thromboembolic pulmonary hypertension (CTEPH) is a distinct pulmonary vascular disease, categorized as group IV in the WHO classification of pulmonary hypertension (PH). 1 CTEPH still remains a serious disorder because it is associated with progressive PH, leading to severe right ventricular failure and death. 2 The main feature of CTEPH, as opposed to pulmonary arterial hypertension, is obstruction of pulmonary arteries (PA) by organized thrombi that are resistant to fibrinolysis. [2] [3] [4] [5] [6] Although CTEPH has long been considered to simply occur after acute pulmonary embolism, 7, 8 it is frequently noted in patients without any previous clinical episodes of acute pulmonary embolism or deep vein thrombosis. 9 Moreover, most patients with CTEPH are free from the traditional risk factors for venous thromboembolism. 10 Thus, the pathogenesis of CTEPH still remains obscure. Pulmonary vascular beds are continuously exposed to circulating microthrombi and contribute to their filtration and fibrinolysis. 11 The interaction between microthrombi and PA endothelial cells (PAECs) is the initial step for thrombolysis. 12, 13 Thus, there should be a key molecular factor(s) involved in the interactions between local pulmonary vascular beds and microthrombi.
We have recently demonstrated that plasma levels of thrombin-activatable fibrinolysis inhibitor (TAFI, also known as carboxypeptidase B2, encoded by CPB2) are significantly elevated in CTEPH patients compared with pulmonary arterial hypertension patients or controls.
14 Additionally, we demonstrated the minor allele of CPB2 in CTEPH patients compared with the standard Asian population.
14 TAFI is a glycoprotein that is cleaved and activated by the interaction with thrombin and thrombomodulin (TM) in vascular beds. 15, 16 The activated form of TAFI (TAFIa) reduces plasmin activity and inhibits fibrinolysis. 17 We found that plasma levels of TAFIa are negatively correlated with clot lysis time in CTEPH patients. 14 Thus, we hypothesized that TAFI is directly involved in the pathogenesis of thrombus formation in PA, promoting the development of CTEPH. To test this hypothesis, in the present study, we used 3 genetically modified mice of TAFI, including systemic knockout mice, systemic overexpressing mice, and liver-specific overexpressing mice in combination with bone marrow (BM) transplantation technique. Here, we report a line of evidence that TAFIa levels are markedly increased not only in the plasma but also in PA in CTEPH patients and that plasma TAFI is activated by TM locally in pulmonary vascular beds, inhibiting fibrinolysis and promoting thrombus formation and PH in mice. Importantly, peroxisome proliferator-activated receptor-α (PPARα) agonists significantly reduced TAFI synthesis by the liver, with a resultant amelioration of PH in mice and rats. Thus, our data suggest that TAFIa could be a novel and realistic therapeutic target of CTEPH.
Methods
An expanded Methods section is available in the Online Data Supplement.
Results

Activation of Plasma TAFI in CTEPH Patients
We have recently reported that CTEPH patients have higher plasma levels of total TAFI (TAFIa plus nonactivated TAFI) assessed by enzyme-linked immunosorbent assay (ELISA) and higher prevalence of single nucleotide polymorphisms of CPB2 compared with controls. 14 Here, we further performed Western blotting to evaluate plasma levels of TAFIa and intact TAFI (TAFI, nonactivated TAFI), separately. Although there was no difference in plasma TAFI levels between patients with CTEPH and those without it or controls, plasma TAFIa levels showed a 10-fold increase in CTEPH patients compared with pulmonary arterial hypertension patients or controls ( Figure 1A ). Similarly, although there was no significant difference in plasma TAFI levels between hypoxic and normoxic mice, plasma TAFIa levels showed a 25-fold increase in hypoxic mice compared with normoxic mice ( Figure 1B) . Interestingly, in the liver, TAFI levels were also significantly increased in hypoxic mice compared with normoxic mice, with no change in TAFIa levels ( Figure 1C ). Moreover, immunostaining showed the presence of TAFI in the pulmonary thrombus of CTEPH patients ( Figure 1D ). Similarly, we detected the endothelial expression of TM, 17 which is a binding partner of TAFI and thrombin ( Figure 1D ; Online Figure II) . These results suggest that TAFI is activated by TM in PAECs to promote the development of CTEPH.
TAFI Deficiency Ameliorates Hypoxia-Induced PH In Vivo
To evaluate the role of TAFI in the pathogenesis of CTEPH, we used systemic Cpb2 -/-mice and littermate controls 
Novelty and Significance
What Is Known?
• Chronic thromboembolic pulmonary hypertension (CTEPH) is a fatal disease; however, its pathogenesis still remains to be fully elucidated.
• Thrombin-activated fibrinolysis inhibitor (TAFI) inhibits fibrinolysis.
What New Information Does This Article Contribute?
• We developed a novel mouse model of CTEPH, on systemic overexpression of TAFI and hypoxia exposure, which showed organized thrombus with multiple obstructions of pulmonary arteries and reduced survival rate.
• Activated TAFI (TAFIa) enhanced pulmonary artery endothelial permeability, smooth muscle cell proliferation, and monocyte/macrophage activation.
• TAFIa inhibitor and peroxisome proliferator-activated receptor-α agonists ameliorated the development of pulmonary hypertension and thrombus formation in the novel model of CTEPH.
This is the first study that demonstrates the pathogenic role of TAFI in CTEPH. Based on the findings of the present study, TAFIa can be regarded as a crucial molecule at the crossroad of inflammation, pulmonary artery remodeling, and thrombus formation in the pathogenesis of CTEPH. Mechanistically, increased plasma levels of TAFIa induced pulmonary artery endothelial cell dysfunction and promoted adjacent pulmonary artery smooth muscle cells proliferation. Three-dimensional computed tomography showed that TAFI-overexpressing mice had multiple pulmonary artery obstructions, which were similar to those of CTEPH patients. Finally, inhibition of TAFIa reduced thrombus formation in pulmonary arteries and improved survival of the mouse model of CTEPH. These findings implicate TAFI as a crucial molecule in the development of CTEPH and thrombus formation, supporting its role as a potential biomarker and therapeutic target. Increased plasma levels of activated thrombin-activatable fibrinolysis inhibitor (TAFI) in chronic thromboembolic pulmonary hypertension (CTEPH) patients. A, Representative Western blot and quantification of intact TAFI (TAFI) and activated TAFI (TAFIa) levels in the plasma from CTEPH patients (n=32) compared with pulmonary arterial hypertension (PAH) patients (n=22) and controls (n=13). B and C, Representative Western blot and quantification of TAFI and TAFIa levels in the plasma (B) and liver homogenates (C) of wild-type mice exposed to normoxia or hypoxia (10% O 2 ) for 3 weeks (n=6 each). D, Representative immunostaining for TAFI and thrombomodulin (TM) of the pulmonary arteries (PA) in CTEPH patients and controls. Scale bars, 50 μm. E, Representative ElasticaMasson (EM) and immunostaining for α-smooth muscle actin (αSMA) of the PAs in Cpb2 -/-and control mice (Cpb2 +/+ ). Scale bars, 50 μm. F, Muscularization of distal PAs with a diameter of 20 to 70 μm in Cpb2 -/-and Cpb2 +/+ mice exposed to normoxia (n=10 each) or hypoxia for 3 weeks (n=14 each). G and H, Right ventricular systolic pressure (RVSP; G) and right ventricular hypertrophy (RVH) assessed by the ratio of right ventricle to left ventricle plus septum weight (H) in Cpb2 +/+ and Cpb2 -/-mice exposed to normoxia (n=10 each) or hypoxia (10% O 2 ) for 3 weeks (n=14 each). I, Representative EM, phosphotungstic acid-hematoxylin (PTAH), and immunostaining for TAFI and TM of the PA thrombus in Cpb2 +/+ mice exposed to hypoxia (10% O 2 ) for 3 weeks. Quantification of PA thrombi per 100 mm 2 lung field in Cpb2 +/+ and Cpb2 -/-mice exposed to normoxia (n=10 each) or hypoxia (10% O 2 ) for 3 weeks (n=14 each). J, Quantification of plasma levels of thrombin-antithrombin complex (TAT) and TM in Cpb2 +/+ and Cpb2 -/-mice exposed to normoxia or hypoxia (10% O 2 ) for 3 weeks (n=6 each). The plasma levels at each point were compared with those at day 0 by analysis of variance (ANOVA) followed by Tukey HSD test for multiple comparisons. K, Quantification of plasma clot lysis time in Cpb2 +/+ and Cpb2 -/-mice exposed to normoxia (n=10 each) or hypoxia (10% O 2 ) for 3 weeks (n=14 each). Results are expressed as mean±SEM. *P<0.05, **P<0.01. Comparisons of parameters were performed with the unpaired Student t test or 2-way ANOVA followed by Tukey HSD test for multiple comparisons. F indicates fully muscularized vessels; N, nonmuscularized vessels; and P, partially muscularized vessels.
(Cpb2
+/+ mice). Hypoxia promotes the cleavage of TAFI, increases plasma levels of TAFIa, 15 and prolongs the clot lysis time. 18, 19 Thus, we used a mouse model of hypoxia-induced PH. Importantly, in wild-type mice, TM expression was high in PAECs (Online Figure III) , but was low in aortic endothelial cells (Online Figure IV) . Under normoxia, the morphology of PAs was similar between Cpb2 -/-and control mice ( Figure 1E ). When exposed to hypoxia for 3 weeks, the animals exhibited increased medial thickness of PAs and muscularized distal PAs with immunoreactivity for α-smooth muscle actin, the extent of which was attenuated in Cpb2 -/-mice than in Cpb2 +/+ mice ( Figure 1E ). Compared with Cpb2 +/+ mice,
Cpb2
-/-mice exhibited fewer muscularized distal PAs after hypoxic exposure ( Figure 1F ). Consistent with these morphological changes, Cpb2 +/+ mice exhibited increased right ventricular systolic pressure, which was significantly attenuated in Cpb2 -/-mice ( Figure 1G ). The increased ratio of the right ventricle to the left ventricle plus the septum weight [RV/ (LV+Sep)] was also attenuated in Cpb2 -/-mice ( Figure 1H ), suggesting a crucial role of TAFI in hypoxia-induced PH. Importantly, chronic hypoxia significantly increased the number of PAs with thrombus in Cpb2 +/+ mice, which was significantly less in Cpb2 -/-mice ( Figure 1I ). Moreover, chronic hypoxia increased plasma thrombin-antithrombin complex in both Cpb2 +/+ and Cpb2 -/-mice ( Figure 1J ). Additionally, hypoxia transiently reduced soluble TM followed by recovery after 21 days ( Figure 1J ), indicating increased binding partners for TAFI activation. Consistently, hypoxia significantly prolonged plasma clot lysis time in Cpb2 +/+ mice, which was significantly lower in Cpb2 -/-mice ( Figure 1K ). These results suggest that TAFI is crucial for enhancing pulmonary thrombus formation, vascular remodeling, and development of hypoxia-induced PH.
TAFI Overexpression Aggravates Hypoxia-Induced PH In Vivo.
To further evaluate the role of TAFI in the pathogenesis of PH, we developed systemic TAFI-overexpressing mice (TAFITg). TAFI-Tg and control mice showed normal growth under physiological conditions and no significant difference in systolic blood pressure or laboratory data (Online Table II ). After 3-week exposure to hypoxia, 38% of the TAFI-Tg mice died, whereas only 4% of the control mice did (Figure 2A ). Hypoxia significantly increased plasma levels of TAFI and TAFIa in both TAFI-Tg and control mice to a greater extent in TAFI-Tg mice than in controls ( Figure 2B ). Under normoxia, the morphology of the PAs was similar between control and TAFI-Tg mice ( Figure 2C ). In contrast, after hypoxia for 3 weeks, alive TAFI-Tg mice exhibited increased muscularization of distal PAs compared with control mice ( Figure 2D ). Consistent with these morphological changes, TAFI-Tg mice exhibited increased right ventricular systolic pressure and right ventricular hypertrophy compared with control mice ( Figure 2E ). These changes in male mice were comparable in female mice (Online Figure V) . Moreover, TAFI-Tg mice, as compared with controls, had an increased number of PA thrombi ( Figure 2F ) and plasma levels of D-dimer ( Figure 2G ). Hypoxia significantly increased plasma levels of thrombin-antithrombin complex and tended to increase those of TM ( Figure 2G ), contributing to TAFI activation as binding partners. Indeed, plasma clot lysis time was significantly prolonged in TAFI-Tg mice compared with control mice ( Figure 2H ). Treatment with carboxypeptidase inhibitor (CPI; TAFIa inhibitor) 20 significantly shortened plasma clot lysis time in TAFI-Tg mice ( Figure 2I ). In contrast, additional human TAFI significantly prolonged plasma clot lysis time in control mice ( Figure 2J ), which was again shortened by CPI. Moreover, plasma clot lysis time was significantly prolonged in TAFI-Tg PAECs compared with control PAECs in situ (Online Figure VIA and VIB) . Likewise, plasma clot lysis time was significantly prolonged in human PAECs transfected with human TAFI compared with those transfected with control plasmid in situ (Online Figure VIC through VIE) . Finally, 3-dimensional computed tomography showed that TAFI-Tg mice had multiple obstructions of PAs after 3 weeks of hypoxia, which was not observed in control mice ( Figure 2K ). These results suggest that TAFI promotes thrombus formation, pulmonary vascular remodeling, and development of hypoxia-induced PH.
TAFI Augments Pulmonary Vascular Inflammation
Pulmonary vascular inflammation is a trigger for thrombus formation and the development of CTEPH. 21, 22 TAFI overexpression augmented hypoxia-induced perivascular inflammation in TAFI-Tg mice (Online Figure VII) , in which we found increased accumulation of perivascular F4/80 + macrophages (Online Figure VIII) . Consistently, TAFI overexpression increased cytokines/chemokines and growth factors in the lung and the serum after hypoxic exposure (Online Figures VIIC and IX). Importantly, TAFI-Tg mice showed a significant increase in platelet-derived growth factor-BB as compared with controls (Online Figure VIIC) . It is widely known that BMderived cells are involved in the pathogenesis of PH. 23, 24 Thus, we considered that TAFI overexpression in BM cells could promote hypoxia-induced PH in TAFI-Tg mice. To address this issue, green fluorescent protein (GFP)-positive BM cells were transplanted into irradiated control and TAFI-Tg mice ( Figure 3A ). After reconstitution of the BM, chimeric mice were exposed to normoxia or hypoxia for 3 weeks. Under normoxia, GFP expression in the whole lung of the chimeric mice was comparable between control and TAFI-Tg mice (Online Figure X) . However, hypoxia enhanced GFP expression and the number of GFP + cells in the PAs of the chimeric mice, the extents of which were greater in TAFI-Tg than in control mice (Figure 3B and 3C; Online Figure X) . Indeed, as shown in the 3D images of distal PAs, abundant GFP + cells adhered to the adventitia in TAFI-Tg recipient mice ( Figure 3D ). To further elucidate the cell phenotypes in the adventitia, we used flow cytometry for analyzing lung cell suspensions from TAFI-Tg and control chimeric mice ( Figure 3E and 3F). 25 The percentages of CD45 + leukocytes in lungs were significantly increased in TAFI-Tg chimeric mice compared with control chimeric mice ( Figure 3E ). Moreover, the percentages of CD45 + CD11b + Ly6G − monocytes/macrophages in lungs were significantly increased in TAFI-Tg chimeric mice compared with control chimeric mice ( Figure 3F ), suggesting a crucial role of monocytes/macrophages in TAFI-mediated PA inflammation. Consistently, the secretions of cytokines/chemokines Figure 2 . Thrombin-activatable fibrinolysis inhibitor (TAFI) overexpression promotes hypoxia-induced pulmonary hypertension (PH) in mice. A, Survival rate of systemic TAFI-overexpressing mice (TAFI-Tg) and control mice exposed to normoxia (n=19 each) or hypoxia (10% O 2 ) for 3 weeks (n=22 each). Results are expressed as log-rank test. B, Representative Western blot and quantification of TAFI and activated TAFI (TAFIa) expression in the plasma from TAFI-Tg and control mice exposed to normoxia or hypoxia (10% O 2 ; n=3 each). Each plasma level was compared with that at day 0 by unpaired Student t test. C, Representative Elastica-Masson (EM) and immunostaining for α-smooth muscle actin (αSMA) of the distal pulmonary arteries (PA) in TAFI-Tg and control mice exposed to normoxia or hypoxia (10% O 2 ) for 3 weeks. Scale bars, 50 μm. D, Muscularization of distal PAs in TAFI-Tg and control mice exposed to normoxia (n=19 each) or hypoxia (10% O 2 ) for 3 weeks (TAFI-Tg, n=14; controls, n=21). E, Right ventricular systolic pressure (RVSP) and right ventricular hypertrophy (RVH) in TAFI-Tg and control mice exposed to normoxia (n=19 each) or hypoxia (10% O 2 ) for 3 weeks (TAFI-Tg, n=14; controls, n=21). F, Quantification of number of PA thrombus per 100 mm 2 lung field in TAFI-Tg and control mice exposed to normoxia (n=19 each) or hypoxia (10% O 2 ) for 3 weeks (TAFI-Tg, n=14; controls, n=21). G, Plasma levels of D-dimer, thrombin-antithrombin complex (TAT), and thrombomodulin (TM) in TAFI-Tg and control mice exposed to normoxia or hypoxia (10% O 2 ) for 3 weeks (n=8 each). H, Measurement of plasma clot lysis time (CLT) in TAFITg and control mice exposed to normoxia (n=19 each) or hypoxia (10% O 2 ) for 3 weeks (TAFI-Tg, n=14; controls, n=21). I, Measurement of plasma CLT in TAFI-Tg mice. The plasma was mixed with a TAFIa inhibitor (25 μg/mL) or vehicle (n=19 each). J, Measurement of plasma CLT in control mice. The plasma was mixed with human TAFI (hTAFI; 1 nmol/L), TAFIa inhibitor (25 μg/mL), or vehicle (n=19 each). K, Representative images of 3-dimensional computed tomography (3D-CT) of PAs in TAFI-Tg and control mice. Quantification of frequency of obstruction in large PAs detected by 3D-CT (n=12 each). Results are expressed as mean±SEM. *P<0.05, **P<0.01. Comparisons of parameters were performed with the unpaired Student t test or 2-way analysis of variance (ANOVA) followed by Tukey HSD test for multiple comparisons. F indicates fully muscularized vessels; N, nonmuscularized vessels; and P, partially muscularized vessels.
and growth factors were significantly increased in PA smooth muscle cells (PASMCs) harvested from the distal PAs of TAFI-Tg mice compared with controls (Online Figure XIA) . Thus, contrary to our original notion, these results indicate that enhanced PA inflammation in TAFI-Tg mice is because of upregulated TAFI in the recipient lung. Again, PA thrombus formation was consistently increased in TAFI-Tg mice compared with controls ( Figure 3G) . Similarly, the extent of ) were transplanted into irradiated TAFI-overexpressing mice (TAFI-Tg) or control mice. After reconstitution of the BM, the chimeric mice were exposed to hypoxia (10% O 2 ) for 3 weeks. B, Representative immunostaining for green fluorescent protein (GFP; green), α-smooth muscle actin (αSMA; Cy3, red), and DAPI (blue) of lung sections from TAFI-Tg and wild-type (WT) recipient mice with GFP + BM exposed to normoxia or hypoxia (10% O 2 ) for 3 weeks. Scale bars, 50 μm. C, Quantification of GFP + cells per 100 mm 2 lung field in TAFI-Tg and WT recipient mice with GFP + BM in normoxia (n=10 each) or hypoxia (10% O 2 ) for 3 weeks (n=12 each). D, Representative 3-dimensional (3D) images of immunostaining for GFP (green), αSMA (Cy3, red), and DAPI (blue) of the distal pulmonary arteries (PAs) in TAFI-Tg and WT recipient mice with GFP + BM exposed to normoxia or hypoxia (10% O 2 ) for 3 weeks. Scale bars, 50 μm. E, Lung cell suspensions within the forward scatter (FSC)/side scatter (SSC) gate were analyzed for CD45 + positivity (red) against SSC. Quantification of CD45 + cells in WT and TAFI-Tg mice (n=10 each PH was still severe in TAFI-Tg mice compared with controls even after BM reconstitution ( Figure 3H ). To further confirm the role of TAFI in BM-derived cells, Cpb2 +/+ and Cpb2 -/-BM cells were transplanted into irradiated Cpb2 +/+ mice ( Figure 3I ). Complete blood count was comparable between the chimeric mice (Online Table III ). Again, there was no significant difference in right ventricular systolic pressure, right ventricular hypertrophy, or thrombus formation between the chimeric mice ( Figure 3J ), indicating that TAFI in the lung, but not in the BM, causes PA inflammation and PH.
Plasma TAFI Promotes Hypoxia-Induced Thrombus Formation and PH
Although immunostaining showed the presence of TAFI in the lung of CTEPH patients ( Figure 1D ), TAFI is known to be synthesized mainly by the liver and is released into the plasma. 17 Here, to further examine the role of TAFI in the plasma, we overexpressed TAFI in the liver by using an albumin promoter-driven recombinant plasmid (pLIVE [plasmid for liver in vivo expression]-human TAFI). Then, the liverspecific TAFI-overexpressing mice (TAFI-P) and mice with control plasmid were exposed to hypoxia for 3 weeks ( Figure  4A ). Western blotting showed that both the plasma and the liver levels of TAFI were significantly increased in TAFI-P mice compared with mice with control plasmid ( Figure 4B ). After 3 weeks of exposure to hypoxia, the number of PA thrombi was significantly increased in TAFI-P mice compared with mice with control plasmid ( Figure 4C ). Consistently, plasma clot lysis time was significantly prolonged in TAFI-P mice compared with mice with control plasmid ( Figure 4D ). Additionally, increased plasma TAFI reduced vascular endothelial cadherin (VE-cadherin) expression and increased . Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) promotes hypoxia-induced thrombus formation and pulmonary hypertension (PH). A, Recombinant plasmid protocol to develop liver-specific TAFI-overexpressing mice. Liver-specific TAFIoverexpressing plasmid is human TAFI plasmid cloned into pLIVE (plasmid for liver in vivo expression) vector. The recombinant plasmid and control plasmid were injected through the tail vein of wild-type (WT) mice. After 1 week, WT mice treated with recombinant plasmid (TAFI-P) and control plasmid (Ctrl-P) were exposed to hypoxia (10% O 2 ) for 3 weeks. B, Representative Western blot and quantification of TAFI, activated (TAFIa), and β actin expression in the plasma and liver homogenates of TAFI-P and Ctrl-P mice exposed to normoxia for 3 weeks (n=6 each). C, Quantification of the number of pulmonary artery (PA) thrombus in TAFI-P and Ctrl-P mice exposed to normoxia (n=10 each) or hypoxia (10% O 2 ) for 3 weeks (n=14 each). D, Quantification of plasma clot lysis time in TAFI-P and Ctrl-P mice exposed to normoxia (n=10 each) or hypoxia (10% O 2 ) for 3 weeks (n=14 each). E, Western blot assessments of vascular endothelial cadherin (VEcadherin)/α-tubulin and phosphorylated/total extracellular signal-regulated kinase (ERK)1/2 in lung homogenates of TAFI-P and Ctrl-P mice exposed to normoxia (n=6 each) or hypoxia (10% O 2 ) for 3 weeks (n=6 each). F, Right ventricular systolic pressure (RVSP) and right ventricular hypertrophy (RVH) in TAFI-P and Ctrl-P mice exposed to normoxia (n=10 each) or hypoxia (10% O 2 ) for 3 weeks (n=14 each). Results are expressed as mean±SEM. *P<0.05, **P<0.01. Comparisons of parameters were performed with the unpaired Student t test or 2-way analysis of variance (ANOVA) followed by Tukey HSD test for multiple comparisons. extracellular signal-regulated kinase 1/2 signaling in the lung ( Figure 4E ). Finally, TAFI-P mice showed severe PH ( Figure  4F ), suggesting that plasma TAFI directly promotes the development of thrombus formation and PH.
Plasma TAFI Enhances PAEC Permeability and PASMC Proliferation
Considering the importance of increased plasma levels of TAFI in CTEPH, we considered that plasma TAFI may directly affect PAECs to induce endothelial dysfunction. Indeed, TAFI was also expressed in PAECs of CTEPH patients (Online Figure II) , implicating the adhesion of plasma TAFI to PAECs. To address this issue, we treated PAECs with human TAFI and examined the changes in multiple genes that regulate endothelial function. Interestingly, human TAFI significantly increased mRNA level of vascular cell adhesion molecule-1 and reduced that of VE-cadherin and tPA (tissue-type plasminogen activator; Figure 5A ). Additionally, human TAFI significantly reduced VE-cadherin protein level ( Figure 5B ) and staining ( Figure 5C ). Moreover, tube formation assay demonstrated that human TAFI significantly reduced angiogenesis in PAECs (Online Figure XIIA) . TM is highly expressed in PAECs 26 and binds TAFI for its activation through interaction with thrombin.
27,28 Thus, we considered that TM is crucial for TAFI-mediated VE-cadherin downregulation in PAECs. Interestingly, TM siRNA significantly attenuated TAFI-mediated VE-cadherin downregulation ( Figure 5B ). Moreover, TM siRNA reduced TAFIa in conditioned medium, a consistent finding with the previous reports that TM in PAECs contributes to TAFI activation ( Figure 5B) . 27, 28 In contrast, in human aortic endothelial cells, TAFI-mediated VE-cadherin downregulation (Online Figure  XIIB) and TM expression ( Figure 5D ) were significantly less compared with PAECs. Interestingly, treatment with human TAFI significantly reduced oxygen consumption rate and increased extracellular acidification rate in PAECs compared with vehicle, suggesting that TAFI dysregulates the metabolic homeostasis and function of PAECs ( Figure 5E and 5F). These results suggest that TM is crucial for TAFI activation and endothelial dysfunction, which is a plausible mechanism for the pulmonary vasculature-selective occurrence of vascular lesions in CTEPH patients.
VE-cadherin regulates endothelial permeability, 29, 30 which is important in the pathogenesis of PH. 31 Thus, we next examined PAEC permeability after human TAFI treatment. Interestingly, human TAFI significantly increased PAEC permeability ( Figure 5G ), whereas it had no effects in aortic endothelial cells. Additionally, knockdown of TM or VE-cadherin significantly reduced TAFI-mediated increase in PAEC permeability ( Figure 5H ). Here, we performed permeability assay after treatment with CTEPH plasma. Compared with control plasma, CTEPH plasma significantly increased PAEC permeability, which was partially attenuated by a TAFIa inhibitor ( Figure 5I ). Consistently, CTEPH plasma significantly downregulated VE-cadherin in PAECs, which was again attenuated by a TAFIa inhibitor (Online Figure XIIC) . Finally, plasma levels of TAFIa positively correlated with PAEC permeability (Figure 5J ), suggesting that plasma TAFIa promotes PAEC permeability through TM in CTEPH patients.
Increased endothelial permeability will expose PASMCs to plasma TAFIa, which may promote cell proliferation. To address this issue, we examined PASMC apoptosis and proliferation after treatment with human TAFI. Human TAFI activated extracellular signal-regulated kinase 1/2 ( Figure 6A ), reduced caspase-3 expression ( Figure 6B ), and increased PASMC proliferation ( Figure 6C ). Consistently, proliferation of PASMCs harvested from the distal PAs of TAFI-Tg mice was significantly increased compared with control mice (Online Figure XIB) . To further confirm the role of increased plasma TAFIa in CTEPH patients, we performed cell proliferation assays with PASMCs after treatment with CTEPH plasma. Treatment with CTEPH plasma significantly increased extracellular signal-regulated kinase 1/2 activity ( Figure 6D ) and cell proliferation in PASMCs ( Figure 6E ) as compared with control plasma. This proliferative effect was attenuated by a TAFIa inhibitor ( Figure 6E ). Finally, plasma levels of TAFIa positively correlated with PASMC proliferation ( Figure 6F ), suggesting that TAFIa promotes PASMC proliferation in CTEPH patients ( Figure 6G ).
TAFIa Inhibition Ameliorates Hypoxia-Induced PH
To evaluate the effects of TAFIa inhibition in hypoxia-induced PH in mice, we first performed in silico screening using the Life Science Knowledge Bank software (http://www.lskb.wfusionus.com/) and found several TAFIa inhibitors in the database (Online Data Set). Among the TAFIa inhibitors, we chose CPI (IC 50 =2.1 nmol/L) to perform in vivo experiments. After 3-week exposure to hypoxia, 25% of the TAFI-Tg mice with vehicle died, whereas only 6% of the TAFI-Tg mice with CPI treatment did ( Figure 7A ). CPI treatment significantly reduced plasma levels of TAFIa ( Figure 7B ), reduced clot lysis time and clot formation ( Figure 7C ), and ameliorated hypoxia-induced PH in both TAFI-Tg and control mice ( Figure 7D ), demonstrating the beneficial effects of the TAFIa inhibitor for the treatment of PH.
PPARα Agonists Ameliorate Animal Models of PH
We further examined TAFI inhibitors that are currently used in clinical settings and found PPARα agonists. Consistent with the hypoxia-induced increase in TAFI in the liver ( Figure  1C ), hypoxia significantly increased TAFI synthesis by hepatocytes (HepG 2 cell lines; Online Figure XIIIA) . We examined the possible therapeutic effects of the PPARα agonists as they have been reported to suppress TAFI synthesis by hepatocytes. 32 Importantly, hypoxia-induced synthesis and secretion of TAFI were significantly attenuated by a selective PPARα agonist, WY14643, in a concentration-dependent manner (Online Figure XIIIA) . We further confirmed that partial PPARα agonists (WY14643, fenofibrate, bezafibrate, and clofibrate) and a PPARγ agonist (GW1929) inhibit TAFI mRNA, whereas a high-affinity PPARδ agonist (GW0742) had no effects (Online Figure XIIIB) . Additionally, Western blotting showed that PPARα agonists, especially WY14643 and fenofibrate, inhibited TAFI protein levels in both cell lysates and conditioned medium ( Figure 7E ; Online Figure  XIIIC) . Moreover, hypoxia-inducible factor-1α (HIF-1α) knockdown by siRNA significantly reduced the secretion of TAFI (Figure 7E) , suggesting an involvement of HIF-1α in Figure 5 . Thrombin-activatable fibrinolysis inhibitor (TAFI) induces pulmonary artery endothelial cell (PAEC) dysfunction and permeability. A, Quantification of mRNA expression of vascular endothelial cadherin (VE-cadherin; VE-cad), tPA (tissue-type plasminogen activator), zona occludens protein-1 (ZO-1), prostaglandin I 2 (PGI 2 ), endothelial NOS (eNOS), interleukin (IL)-8, junctional adhesion molecules (JAM), IL-6, plasminogen activator inhibitor-1 (PAI-1), BCL2-associated X protein (BAX), bone morphogenetic protein receptor type II (BMPR2), platelet endothelial cell adhesion molecule-1 (PECAM), apelin (APLN), intercellular adhesion molecule (ICAM)-1, and vascular cell adhesion molecule (VCAM)-1 in human pulmonary artery endothelial cells (PAECs) treated with human TAFI (hTAFI, 300 nmol/L) for 24 h (n=4 samples per group). For the statistical analyses, unpaired Student t test was used. B, Representative Western blot and quantification of VE-cad, TAFI, TAFIa, and α-tubulin expression in total cell lysates (TCL) and conditioned medium (CM) of human PAECs treated with hTAFI (300 nmol/L) for 24 h after transfection with thrombomodulin siRNA (si-TM) or control siRNA (si-Ctrl; n=4 samples per group). C, Representative immunostaining for VE-cadherin (red) and DAPI (blue) of human PAECs treated with hTAFI (300 nmol/L) for 24 h. D, Quantification of mRNA expression of TM in human PAECs and aortic endothelial cells (AoECs). E, Quantification of basal oxygen consumption rate (OCR) and max respiration capacity in human PAECs treated with TAFI protein (300 nmol/L) for 24 h (n=5 samples per group). F, Basal extracellular acidification rate (ECAR) and OCR/ECAR ratio in human PAECs treated with TAFI protein (300 nmol/L) for 24 h (n=5 samples per group). G, Quantification of the permeability in the cell layer of human pulmonary PAECs and AoECs treated with hTAFI (300 nmol/L) for 24 h (n=10 samples per group). H, Quantification of the permeability in PAEC layer treated with hTAFI (300 nmol/L) for 24 h after transfection with si-TM, si-VE-cad, both siRNA (si-both), and si-Ctrl (n=10 samples per group). I, Quantification of the permeability in PAEC layer treated with the plasma from chronic thromboembolic pulmonary hypertension (CTEPH) patients (n=32) and controls (n=13) for 24 h. The plasma was mixed with a TAFIa inhibitor (25 μg/mL) or vehicle. J, Correlation between PAECs permeability and plasma levels of activated TAFI (TAFIa) in CTEPH patients (n=32). Results were analyzed with Pearson rank correlation coefficient. Results are expressed as mean±SEM. *P<0.05, **P<0.01. Comparisons of parameters were performed with the unpaired Student t test or 2-way ANOVA followed by Tukey HSD test for multiple comparisons. Figure 7F ). After 3-week exposure to hypoxia, HIF-1α expressions in the liver were significantly upregulated in both TAFI-Tg and control mice, which were again downregulated by WY14643 treatment ( Figure  7G ). Additionally, WY14643 downregulated HIF-1α expression in hepatocytes (HepG2; Online Figure XIV) . Moreover, WY14643 significantly reduced plasma D-dimer (Online Figure XIIIE) , clot lysis time, and PA thrombus formation in both TAFI-Tg and control mice ( Figure 7H ), resulting in the amelioration of PH in both TAFI-Tg and control mice ( Figure  7I ; Online Figure XIIIG) . Interestingly, WY14643 treatment significantly reduced pulmonary vascular permeability in both TAFI-Tg and control mice ( Figure 7J ). Consistently, serum levels of inflammatory cytokines and growth factors (eg, interleukin [IL]-1β, IL-6, GM-CSF [granulocyte macrophage colony-stimulating factor], interferon-γ, and tumor necrosis factor-α) were significantly reduced, especially in TAFI-Tg mice by WY14643 treatment (Online Figure XV) . Finally, to further confirm the role of PPARα agonists, we used additional 2 rat models of PH; monocrotaline-induced PH and Sugen/ hypoxia-induced PH ( Figure 8A and 8E) . Plasma levels of TAFIa were significantly increased in both models, which were significantly reduced by WY14643 treatment (Figure 8B and 8F). Moreover, we found significantly increased clot lysis time and PA thrombus formation in the lungs of both models, which were reduced by WY14643 ( Figure 8C and 8G) . Consistently, WY14643 treatment significantly ameliorated PH in both rat models ( Figure 8D and 8H) .
Discussion
Considerable efforts have been devoted to understand the pathogenesis of CTEPH, which is caused by residual thromboemboli with flaps and meshwork formation in the PAs. 33 However, the molecular pathogenesis of CTEPH has long been elusive. 34, 35 To the best of our knowledge, this is the first study that demonstrates the pathogenic role of TAFI in CTEPH. The major findings of the present study are that (1) plasma levels of TAFIa were markedly increased in CTEPH patients and hypoxic mice, (2) TAFI knockdown attenuated the development of hypoxia-induced PH, (3) TAFI overexpression promoted the development of hypoxia-induced PH and thrombus formation, (4) 3-dimensional computed tomography showed multiple obstruction of PAs in TAFI-overexpressing mice, (5) the plasma from CTEPH patients enhanced PAEC permeability and PASMC proliferation, and (6) TAFIa inhibitor and PPARα agonists reduced plasma TAFI and ameliorated the development of PH in mice and rats. Based on these findings, we propose the crucial role of plasma TAFIa in the development of PH and thrombus formation in PAs.
TM-Mediated TAFI Activation in PAECs
Hypoxia increases plasma TAFIa 15 and promotes the development of PH. 1 Consistently, we detected a 25-fold increase in plasma TAFIa in hypoxic mice. In accordance with the increase in plasma TAFIa, hypoxic mice showed enhanced thrombus formation in PAs. PAECs highly express TM, 26 a binding partner of thrombin and TAFI, by which TAFI is cleaved and activated. 17 Importantly, TM expression in PAECs was enhanced in patients with CTEPH compared with controls. Likewise, TM expression in PAECs was enhanced in hypoxic mice compared with normoxic mice. Additionally, hypoxia significantly increased plasma levels of thrombinantithrombin complex, which is an indicator of plasma levels of thrombin. Thus, it is possible that chronic hypoxia will increase the TM-thrombin-TAFI complex on the surface of PAECs, promoting cleavage and activation of plasma TAFI in pulmonary vascular beds. Conversely, TM knockdown in PAECs reduced cleavage and activation of human TAFI in the culture medium, supporting the TM-mediated TAFI activation. 27, 28 Moreover, TM knockdown attenuated TAFI-mediated VE-cadherin downregulation and permeability in PAECs. However, these TAFI-mediated changes were absent in aortic endothelial cells, which express lower levels of TM compared with PAECs. Thus, TM-mediated TAFI activation and endothelial permeability is one of the plausible mechanisms for the pulmonary vasculature-selective occurrence of vascular lesions in patients.
Mechanisms for TAFI Activation in CTEPH Patients
Based on the present results and the previous reports, the increased plasma levels of TAFIa in CTEPH patients can be explained in part by the increased TM in PAECs and thrombin in the plasma. However, it remains unclear why TAFI is Figure 7 Continued. Representative Western blot and quantification of TAFI and TAFIa in the plasma from TAFI-Tg and control mice exposed to hypoxia for 3 weeks with CPI (5 mg/kg/d) or vehicle (n=4 each). C, Clot lysis time and the number of pulmonary artery (PA) thrombi in TAFI-Tg and control mice exposed to hypoxia for 3 weeks with CPI (5 mg/kg/d) or vehicle (n=12 each). D, Right ventricular systolic pressure (RVSP) and right ventricular hypertrophy (RVH) in TAFI-Tg and control mice exposed to hypoxia for 3 weeks with CPI (5 mg/kg/d) or vehicle (n=12 each). E, Representative Western blot and quantification of TAFI and TAFIa in conditioned medium (CM) of HepG 2 cells treated with WY14643 (10 μM) for 24 h after transfection with hypoxia-inducible factor-1α (HIF-1α) si-RNA (si-HIF-1α) or control siRNA (si-Ctrl; n=3 each). F, Representative Western blot and quantification of TAFI, TAFIa, and β-actin in the liver and the plasma of TAFI-Tg and control mice exposed to hypoxia for 3 weeks with WY14643 (3 mg/kg/d) or vehicle (n=4 each). G, HIF-1α mRNA expression in the liver from TAFI-Tg and control mice exposed to hypoxia with WY14643 (n=10 each) or vehicle (n=12 each). H, Clot lysis time and the number of PA thrombi in TAFI-Tg and control mice exposed to hypoxia with WY14643 (3 mg/kg/d; n=12 each) or vehicle (n=30 each) for 3 weeks. I, RVSP and RVH in TAFI-Tg and control mice exposed to hypoxia for 3 weeks with WY14643 (3 mg/kg/d; n=12 each) or vehicle (n=30 each). J, Representative confocal images of immunostaining for FITC-dextran (green), vascular endothelial cadherin (VE-cadherin; red), and DAPI (blue) and quantification of PA permeability in TAFI-Tg and control mice exposed to hypoxia for 3 weeks with WY14643 (3 mg/kg/d) or vehicle (n=8 each). Results are expressed as mean±SEM. *P<0.05, **P<0.01. Comparisons of parameters were performed with the unpaired Student t test or 2-way analysis of variance (ANOVA) followed by Tukey HSD test for multiple comparisons.
10-fold more activated in CTEPH patients compared with controls. One of the possible mechanisms is the difference in the genetic background of CTEPH patients. As we have recently reported, there is a prevalence of the minor allele of CPB2 in CTEPH patients compared with the standard population.
14 Indeed, it has been reported that the single nucleotide polymorphisms of CPB2 (eg, −1120 G/T; rs799916836 and −1583 A/T; rs108737) were related to the elevation of plasma TAFI levels. [36] [37] [38] Importantly, it has been reported that Thr325/ Ile (rs192644738) is associated with differences in TAFIa stability. 38 Among those single nucleotide polymorphisms, we detected the minor allele of rs7999168 in 24% of patients, that of rs1926447 in 24%, and that of rs1087 in 35%.
14 The prevalence of the minor allele of CPB2 in CTEPH patients is higher compared with the that in standard Asian population in the HapMap. 39 However, we need to increase the number of CTEPH patients to elucidate the role of single nucleotide polymorphisms in the pathogenesis of CTEPH. Additionally, there may be other minor allele of THBD (TM gene), F2 (thrombin gene), and F2Rs (thrombin receptor family genes), all of which may play crucial roles in the activation of TAFI in the plasma. Specifically, we can speculate that some minor alleles may increase the binding affinity of TAFI for TM or strengthen the interaction with thrombin. However, further rigorous analyses, especially targeting TM, thrombin, and other coagulation factors, are needed to explain the increase in TAFIa levels in CTEPH patients. For this purpose, we have recently started the registration of CTEPH patients and analyses of whole-genome sequencing. Further studies into the specific mechanism of TAFI cleavage and activation would provide important additional insights into the pathogenesis of CTEPH.
In addition to these genetic backgrounds, additional environmental factors (eg, infection, inflammation, residence, air pollutions, smoking, and especially hypoxia) would result in complex interactions and trigger the activation of TAFI in CTEPH patients. Plasma levels of TAFIa were significantly increased in mice by hypoxia. Consistently, plasma levels of TAFIa were significantly increased in CTEPH patients. Synthesis and secretion of TAFI were regulated by HIF-1α signaling that mediates hypoxia-induced increases in multiple inflammatory cytokines/chemokines and growth factors. In contrast, expressions of HIF-1α mRNA in the liver were equally upregulated by hypoxia in both control and TAFI-Tg mice, which were significantly downregulated by WY14643 treatment. Additionally, WY14643 treatment downregulated HIF-1α expression in hepatocytes in vitro. However, these WY14643-mediated HIF-1α downregulations in vivo and in vitro were potentially the consequences of indirect effects of suppression of inflammatory cytokines. Indeed, WY14643 significantly reduced serum levels of cytokines/chemokines and growth factors in TAFI-Tg mice. Moreover, it has been demonstrated that inflammatory cytokines (eg, IL-1β, IL-6, and IL-18) activate intracellular signaling and transcription factors that are recruited to the hypoxia-responsive element in the HIF-1α promoter. [40] [41] [42] [43] Thus, WY14643-mediated reductions in circulating inflammatory cytokines may have downregulated HIF-1α activity in the liver. Importantly, the levels of HIF-1α activity in the liver were comparable between the control and TAFI-Tg mice, suggesting that TAFI protein itself would not affect HIF-1α activity. In contrast, in mice treated with vehicle in hypoxia for 3 weeks, serum levels of cytokines/chemokines and growth factors (eg, IL-1β, IL-6, G-CSF [granulocyte colony-stimulating factor], RANTES [regulated on activation, normal T-cell expressed and secreted], tumor necrosis factor-α, and platelet-derived growth factor-BB) were significantly higher in TAFI-Tg mice compared with control mice. Additionally, in vitro experiments with mouse PASMCs and secretion of inflammatory cytokines (eg, IL-1β and IL-6) were significantly increased in TAFI-Tg PASMCs compared with control PASMCs. Moreover, PASMC proliferation in response to 10% FBS was significantly higher in TAFI-Tg PASMCs compared with control PASMCs. These results suggest that TAFI protein itself may have proinflammatory effects and promotes secretion of inflammatory cytokines and growth factors. On the other hand, WY14643-mediated reductions of circulating inflammatory cytokines should have beneficial effects on pulmonary vasculature, including an improvement of PAEC function, reduced adhesion molecule expression, reduced PASMC proliferation, and deactivation of inflammatory cells. Thus, PPARα agonists may have multiple effects on the pulmonary vasculature in addition to the downregulation of HIF-1α-mediated TAFI synthesis. Altogether, we could offer some mechanistic explanations for the WY14643-mediated amelioration of PH, which were associated with the inhibitory effects on TAFI synthesis and the anti-inflammatory effects on pulmonary vasculature.
TAFI-Mediated Pulmonary Vascular Inflammation
Increased endothelial permeability is one of the important features of PH because it promotes the translocation of inflammatory factors across the vascular wall. 31, 44 Recent studies clearly demonstrated the role of VE-cadherin for endothelial permeability. 29, 45 In the present study, treatment with human TAFI reduced VE-cadherin expression and increased PAEC permeability. In vivo, it is possible that the increased endothelial permeability exposes PASMCs to plasma TAFI and other circulating growth factors. Indeed, in the present study, treatment with human TAFI significantly increased extracellular signal-regulated kinase 1/2 phosphorylation and PASMCs proliferation. Moreover, the secretions of cytokines/chemokines and growth factors were significantly increased in PASMCs harvested from the distal PAs of TAFI-Tg mice, supporting the autocrine/paracrine effects of TAFI for PASMC activation and proliferation. Consistently, TAFI overexpression increased cytokines/chemokines and growth factors in the lung after hypoxic exposure, suggesting the crucial role of TAFI in hypoxia-induced pulmonary vascular inflammation. This is consistent with the previous report that TAFI promotes lung inflammation in a mouse model of sepsis. 46 Because inflammation plays a crucial role for the development of PH, 47, 48 TAFI-mediated enhancement of perivascular inflammation substantially contributes to the development of pulmonary vascular remodeling and PH. Based on these results and the previous reports, TAFI promotes pulmonary vascular remodeling and PH through increasing PAEC permeability, PASMC proliferation, and augmented inflammation. However, we still do not know the precise mechanisms underlying the TAFIinduced VE-cadherin downregulation and PASMC proliferation. Indeed, the receptors for TAFI in PAECs or PASMCs remain unidentified. Further studies into the specific mechanism of TAFI-mediated intracellular signaling in PAECs and PASMCs would provide important additional insights into the pathogenesis of PH.
Several limitations should be mentioned for the present study. First, we showed that TAFI in BM cells did not contribute to the development of PH or thrombus formation. However, BM-derived cells are the source of several types of cells including platelets. In the present BM experiments, we were unable to distinguish the roles of TAFI in each cell component. Indeed, we already reported that platelets in CTEPH patients are highly activated 6 and release TAFI into the plasma. 14 Thus, BM-derived TAFI, especially from platelets, may play a crucial role in the development of PH. Next, the beneficial effects of PPARα agonists may involve factors other than reducing plasma TAFIa. Indeed, PPARα agonists regulate lipid metabolism and blood pressure, oxidative stress, and inflammation. 49, 50 Moreover, PPARα agonists have been reported to reduce plasma levels of fibrinogen. 51 Thus, PPARα agonists may ameliorate PH by reducing plasma TAFIa and by other mechanisms.
Clinical Implication and Conclusions
Patients with CTEPH show no typical signs or symptoms at the onset of the disease and have no typical risk factors. 52 Although pulmonary embolism is considered as one of the predictive factors for the development of CTEPH, the incidence was not so high (<10%) in the international prospective registry. 7, 8 Thus, it is difficult to diagnose CTEPH and predict the risk in clinical practice. Additionally, most of the established diagnostic techniques are invasive, including cardiac catheterization. In the present study, we demonstrated that CTEPH patients have a 10-fold increase in plasma TAFIa compared with controls, suggesting the usefulness of plasma TAFIa as a novel biomarker for CTEPH. Plasma levels of TAFIa can be easily measured in outpatient clinics and, thus, could be widely used for clinical application. Further accumulation of evidence with clinical studies will establish the importance of plasma TAFIa as a novel biomarker in CTEPH patients.
Next, we showed that PPARα agonists reduced plasma TAFIa levels and thrombus formation, which has the potential to cure CTEPH patients. PPARs are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors, which are mainly related to lipid metabolism, insulin sensitivity, and glucose homeostasis. 44 Several studies indicated that PPAR agonists suppress inflammation in endothelial cells and smooth muscle cells. 53, 54 Moreover, PPARγ agonists attenuate the development of hypoxia-induced PH in mice and monocrotaline-induced PH in rats. 55 In contrast, the role of PPARα agonists in PH remained to be elucidated. Importantly, it has also been reported that PPARα agonists regulate fibrinolysis 56 and suppress TAFI synthesis in hepatocytes. 32 Indeed, in the present study, PPARα agonists significantly reduced plasma TAFIa, ameliorated hypoxia-induced PH, and improved survival in TAFI-overexpressing mice. Moreover, these findings were also found in both monocrotaline-induced PH and Sugen/hypoxia-induced PH models in rats. Based on the present results and the previous reports, PPARα agonists may have a potential to be a useful therapeutic option in PH patients. Recently, we and others demonstrated that balloon pulmonary angioplasty improves the prognosis of CTEPH patients. 4 ,33,57 Additionally, we can use vasodilators such as Riociguat for CTEPH patients. 52 However, CTEPH patients still need anticoagulants for the rest of their life, which could cause fatal bleeding and life-threatening events at a higher rate (2%-3%/year). 52 Here, based on the pathogenic role of TAFI in PH, we may consider the use of anticoagulants without the risk of bleeding, such as PPARα agonists or TAFIa-specific inhibitors.
In conclusion, TAFI is a crucial molecule in the development of PH and thrombus formation in PAs and is useful as a novel biomarker and a therapeutic target of CTEPH.
